⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 1, 2003Canadian Public Policy

The Anti-Competitive Effects of Brand-Controlled "Pseudo-Generics" in the Canadian Pharmaceutical Market

View Full Paper

Ask AI

Bookmark

Share

Authors

AHAidan HollisUniversity of Calgary

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Aidan Hollis (2003) studied this question.

synapsesocial.com/papers/6a9dadc5a07850bc91a4dd4b https://doi.org/10.2307/3552486

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

1Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act1992 · 601 citations
2Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry1991 · 411 citations
3The impact of generic goods in the pharmaceutical industry1999 · 58 citations